Baseline score and per cent changes in spontaneous pain, tenderness and motion two weeks (2 wks) after the blind treatment with either alendronate or placebo. The patients were reassessed on week 4, that is, two weeks after a treatment course with intravenous alendronate given to both groups of patients. The score range was 0 to 10 for pain and 0 to 4 for motion score (0 = normal motility)
| Group | Spontaneous pain % decrease (percentiles) | Tenderness % decrease (percentiles) | Motion score % decrease (percentiles) | ||||||||||||||||||||||||
| Range baseline | 2 wks | 4 wks | Range baseline | 2 wks | 4 wks | Range baseline | 2 wks | 4 wks | |||||||||||||||||||
| 10th | 90th | 10th | 90th | 10th | 90th | 10th | 90th | 10th | 90th | 10th | 90th | ||||||||||||||||
| Alendronate blind + alendronate open | 3-8 | −90% | −37% | −90% | −34% | 3-9 | −72% | −21% | −71% | −33% | 2-4 | −50% | 0% | −71% | −17% | ||||||||||||
| Placebo blind + alendronate open | 3-8 | −31% | +12% | −71% | −12% | 3-10 | −33% | +8% | −64% | −17% | 2-4 | −33% | 0% | −67% | −12% | ||||||||||||